scRNAseq data from 4 ASM-AHN, 3 CMML patients and 3 healthy donors

Aggressive systemic mastocytosis with associated hematologic neoplasm (ASM-AHN) represents a complex myeloid neoplasm, in which KIT D816V is the phenotype-defining but not the only driver mutation. Avapritinib is a potent and specific KIT D816V inhibitor recently approved for ASM treatment. To understand the effects of inhibiting KIT D816V on MC and Non-MC compartments, we combined single cell RNA sequencing (scRNAseq) with deep whole genome sequencing (WGS) to map clonal dynamics in successive blood samples from 4 ASM-AHN patients treated with avapritinib (T1 as pretreatment sample, T2 and T3 as posttreatment samples). Since CMML is the most common AHN associated with ASM, we included samples from three treatment-naïve KIT wild type CMML patients for comparison. We also included 3 age-matched healthy donor as controls.